Pharma Mar SA (ES:PHM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharma Mar SA scores a legal victory as the European Commission’s decision to deny marketing authorization for its drug Aplidin is revoked, leading to a dismissal of court proceedings. The company successfully argued a conflict of interest in the original evaluation, and now the European Medicines Agency will re-evaluate the drug for multiple myeloma. The European Commission is ordered to cover its legal costs and those of Pharma Mar.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.